RayKnowChina Research Map
Shortlist

RecruitingBreast cancerPhase 2

Registered title, quoted from ClinicalTrials.gov

Efficacy and Safety of SPH4336 in Combination With Endocrine Therapy in Breast Cancer Patients With Brain Metastases.

An open trial on breast cancer, registered on ClinicalTrials.gov. The lead sponsor is not a hospital on this site; 21 hospitals on this site are listed as study sites.

Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 21

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Study siteAffiliated Cancer Hospital of Xinjiang Medical University新疆医科大学附属肿瘤医院UrumqiHospital page
  2. Study siteAnyang Tumor Hospital安阳市肿瘤医院AnyangHospital page
  3. Study siteFirst Affiliated Hospital of Anhui Medical University安徽医科大学第一附属医院HefeiHospital page
  4. Study siteFirst Affiliated Hospital of Bengbu Medical University蚌埠医学院第一附属医院BengbuHospital page
  5. Study siteFirst Affiliated Hospital of Henan University of Science and Technology河南科技大学第一附属医院LuoyangHospital page
  6. Study siteFirst Affiliated Hospital of USTC中国科学技术大学附属第一医院(安徽省立医院)HefeiHospital page
  7. Study siteFirst Hospital of Jilin University吉林大学第一医院ChangchunHospital page
  8. Study siteFourth Hospital of Hebei Medical University河北医科大学第四医院ShijiazhuangHospital page
  9. Study siteGeneral Hospital of Ningxia Medical University宁夏医科大学总医院YinchuanHospital page
  10. Study siteGuangxi Medical University Cancer Hospital广西医科大学附属肿瘤医院NanningHospital page
  11. Study siteHarbin Medical University Cancer Hospital哈尔滨医科大学附属肿瘤医院HarbinHospital page
  12. Study siteHenan Cancer Hospital河南省肿瘤医院ZhengzhouHospital page
  13. Study siteJiangsu Province Hospital江苏省人民医院(南医大一附院)NanjingHospital page
  14. Study siteJilin Cancer Hospital吉林省肿瘤医院ChangchunHospital page
  15. Study sitePeking Union Medical College Hospital北京协和医院BeijingHospital page
  16. Study sitePeking University Cancer Hospital北京大学肿瘤医院BeijingHospital page
  17. Study siteSun Yat-sen University Cancer Center中山大学肿瘤防治中心GuangzhouHospital page
  18. Study siteTianjin Medical University Cancer Institute & Hospital天津医科大学肿瘤医院TianjinHospital page
  19. Study siteUnion Hospital华中科技大学同济医学院附属协和医院WuhanHospital page
  20. Study siteXiangyang Central Hospital襄阳市中心医院XiangyangHospital page
  21. Study siteZhejiang Cancer Hospital浙江省肿瘤医院HangzhouHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT05872347, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 4

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (4 points)Hide the checklist
  1. 18 years to 75 years; sex: women only

    Registered eligibility fields

  2. ECOG (Eastern Cooperative Oncology Group) performance status score of 0 or 1.

    Inclusion criterion 2

  3. Hepatitis B surface antigen positive and HBV (Hepatitis B Virus) DNA > 2,000 IU/mL or > 10(4) copies/mL; HCV (Hepatitis C Virus) antibody positive and HCV RNA positive; or known HIV infection.

    Exclusion criterion 10

  4. Pregnant or lactating women.

    Exclusion criterion 7

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: diagnosis and how it was confirmed; stage or severity, as the trial defines it; earlier treatment; blood tests: counts, liver and kidney function; scans and measurable lesions.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT05872347, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

  • Patients who voluntarily participate in this study, completely understand this study, and voluntarily sign the informed consent form (ICF).
  • ECOG (Eastern Cooperative Oncology Group) performance status score of 0 or 1.
  • Life expectancy ≥ 3 months.
  • Patients with locally advanced or metastatic breast cancer who are unable to receive radical surgeries/other local therapies.
  • At least one measurable lesion .
  • Laboratory test results meet the relevant requirements for organ function.
  • Subjects who agree to take effective contraceptive measures.

Exclusion Criteria:

  • Inflammatory breast cancer.
  • Patients unsuitable for endocrine therapy at the investigator's discretion.
  • Have a History of other malignancies prior to the start of study treatment.
  • Taking anti-tumor traditional Chinese patent medicines at the time of signing the ICF.
  • Patients who underwent a surgery prior to the start of study treatment, and have not yet recovered from adverse reactions of the surgery.
  • Patients who participated in a clinical trial and received other investigational drugs before the start of study treatment.
  • Pregnant or lactating women.
  • History of myocardial infarction, unstable angina pectoris, severe arrhythmia, and symptomatic congestive heart failure before the start of study treatment; ≥ NYHA (New York Heart Association) Class II; QTcF≥ 470 ms; left ventricular ejection fraction ≤ 50%.
  • History of ischemic stroke or severe thromboembolic disease before the start of study treatment.
  • Hepatitis B surface antigen positive and HBV (Hepatitis B Virus) DNA > 2,000 IU/mL or > 10(4) copies/mL; HCV (Hepatitis C Virus) antibody positive and HCV RNA positive; or known HIV infection.
  • History of severe allergic diseases, history of severe drug allergies, or known allergy to any ingredient of the investigational product.
  • Presence of diseases or conditions that may impact drug administration or gastrointestinal absorption before the start of study treatment.
  • Presence of uncontrolled infections before the start of study treatment.
  • Known history of drug abuse, excessive drinking, or illegal drug use; history of confirmed neurological or mental disorders.
  • Presence of other diseases that the risks of receiving the study treatment outweigh its benefits, as determined by the investigator, or any other reason for which patients are ineligible for the study as assessed by the investigator.

Quoted from ClinicalTrials.gov, NCT05872347, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT05872347, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT05872347